Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units

Genetic Disease Clinical Trial

Official title:

Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02607189
• Other study ID #: PHDehong_NNICU2
• Status: Not yet recruiting
• Phase: N/A
• First received: November 9, 2015
• Last updated: November 14, 2015
• Start date: November 2015
• Est. completion date: December 2020

Study information

• Verified date: November 2015
• Source: The People's Hospital of Dehong Autonomous Prefecture
• Contact: Zhaoqing Yin, bachelor
• Email: zhaoqingyin99[@]sina.com
• Is FDA regulated: No
• Health authority: China: Health and Family planning commision Dehong Autonomous Prefecture of Dai and Jingpo Ethnic Groups,Yunnnan Province
• Study type: Observational

Clinical Trial Summary

The purpose of study is to evaluate the benefits of using the Next Generation Sequencing Technology to diagnose birth defects and genetic diseases. The results from genomic sequencing can also significantly shorten the time of examination, improve the diagnosis rate, guide the clinical treatments. So the ultimate goal is individualized or personalized therapy and promote prognosis.

Description:

Neonatal congenital malformation is one of the most frequent cause of infant death in the western world and major cities of China. There are many different types of congenital malformations, and some of these can be caused by changes in gene mutation. Next generation sequencing (NGS) is a high-throughput parallel sequencing that can provide genetic information with high accuracy. It is a faster and cost-effective method to detect gene mutations compared to Sanger sequencing. We hope to couple genomic techniques with more traditional methods involved in genetic discovery in order to investigate a broad range of conditions for which there is strong evidence that genetic factors are involved. So In this study, we evaluated the clinical role of NGS testing for neonatal genetic disease in newborns compared to Sanger sequencing to observe whether this new technology can significantly shorten the time of examination, improve the diagnosis rate, guide the intervention treatments and promote prognosis.

These neonates who have an undiagnosed illness, and partial families, will be eligible to participate in the study. The study population will be recruited from The People's Hospital of Dehong Autonomous Prefecture, primarily the neonatal intensive care unit(NICU), with a subpopulation presenting to other hospitals in China. All affected study participants will receive a genetic screening according to their clinical symptom. All subjects will have blood drawn for DNA isolation and genomic sequencing at the time of enrollment in the study. All blood sample volumes will adhere to the Fudan University procedure on maximum blood in pediatric patients. In addition, cerebrospinal fluid and tissue samples may be collected and stored in the bank of biosamples. DNA will be isolated and prepared for NGS or Sanger with Fudan protocols at the Translational Medicine Center of Children's Hospital of Fudan University. Partial familial samples will also be obtained, and nucleic acids will also be sequenced, as indicated, to assist in diagnosis of the genetic disease in the newborn. All sequencing data will be stored in the Genome Center Biorepository. In the case of positive study findings that may be diagnostic, our investigator will perform confirmatory clinical diagnostic testing and, if confirmed, a standard clinical diagnostic report will be placed in the patient's medical record. Follow up with the patient's family will be guided by the clinical care team. Both molecular diagnoses results and duration to diagnosis will be recorded as primary outcomes.

In addition, this information will help alleviate anxiety on the part of the family, and also provides a mechanism for patient crossover into the rapid NGS arm if the patient is clinically deteriorating, and at the clinical care team's request. Each time a study participant is enrolled, the clinician and parents will be asked to fill out a survey prior to NGS testing and after return of results. We will also review the patient's medical record and collect clinical variables including laboratory testing, radiology results, medications and other treatments received to further analyze the effect NGS has on clinical care.So the ultimate goal is individualized or personalized therapy. We plan to follow up with families annually up to 18 months post enrollment and record clinical outcomes related to this study.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 2000
• Est. completion date: December 2020
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 28 Days

Eligibility

Inclusion Criteria:

One of the following criteria required.

1. Neonates admitted to the Neonatal Intensive Care Units in one of the study hospitals

2. Clinical genetic testing or a genetic consult is ordered

3. Subject has one major structural anomaly or three or more minor anomalies

4. Abnormal laboratory testing suggestive of a genetic disease

5. Abnormal response to standard therapy for a major underlying condition

Exclusion Criteria:

1. Previously performed exome/genome sequencing on patient

2. Any infant in which clinical considerations preclude drawing 1.0 ml of blood

3. Has features pathognomonic for a large chromosomal aberration (Trisomy 13, 18, 21 or other)

4. Parents are unwilling to have genomic reports placed in the medical record or sent to their primary care pediatrician

5. Parents refuse consent

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Congenital Abnormalities
• Congenital Malformation
• Genetic Disease
• Multiple Malformation

Locations

Country	Name	City	State
n/a

Sponsors (7)

Lead Sponsor	Collaborator
The People's Hospital of Dehong Autonomous Prefecture	Children's Hospital of Fudan University, Guangzhou Women and Children's Medical Center, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Maternal and Child Health Hospital of Hubei Province, Second Affiliated Hospital of Wenzhou Medical University, Xiamen Children's Hospital, Fujian of China

References & Publications (6)

Hamilton ST, van Zuylen W, Shand A, Scott GM, Naing Z, Hall B, Craig ME, Rawlinson WD. Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: a systematic review. Rev Med Virol. 2014 Nov;24(6):420-33. doi: 10.1002/rmv.1814. Epub 2014 Oct 14. Review. — View Citation

Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, Baker M, Ballow M, Bartoshesky LE, Bonilla FA, Brokopp C, Brooks E, Caggana M, Celestin J, Church JA, Comeau AM, Connelly JA, Cowan MJ, Cunningham-Rundles C, Dasu T, Dave N, De La Morena MT, Duffner U, Fong CT, Forbes L, Freedenberg D, Gelfand EW, Hale JE, Hanson IC, Hay BN, Hu D, Infante A, Johnson D, Kapoor N, Kay DM, Kohn DB, Lee R, Lehman H, Lin Z, Lorey F, Abdel-Mageed A, Manning A, McGhee S, Moore TB, Naides SJ, Notarangelo LD, Orange JS, Pai SY, Porteus M, Rodriguez R, Romberg N, Routes J, Ruehle M, Rubenstein A, Saavedra-Matiz CA, Scott G, Scott PM, Secord E, Seroogy C, Shearer WT, Siegel S, Silvers SK, Stiehm ER, Sugerman RW, Sullivan JL, Tanksley S, Tierce ML 4th, Verbsky J, Vogel B, Walker R, Walkovich K, Walter JE, Wasserman RL, Watson MS, Weinberg GA, Weiner LB, Wood H, Yates AB, Puck JM, Bonagura VR. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014 Aug 20;312(7):729-38. doi: 10.1001/jama.2014.9132. Erratum in: JAMA. 2014 Nov 26;312(20):2169. Bonagura, Vincent R [Added]. — View Citation

Matic M, Simons SH, van Lingen RA, van Rosmalen J, Elens L, de Wildt SN, Tibboel D, van Schaik RH. Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype. Pharmacogenomics. 2014 Jul;15(10):1287-95. doi: 10.2217/pgs.14.100. — View Citation

Scully MA, Farrell PM, Ciafaloni E, Griggs RC, Kwon JM. Cystic fibrosis newborn screening: a model for neuromuscular disease screening? Ann Neurol. 2015 Feb;77(2):189-97. doi: 10.1002/ana.24316. Epub 2014 Dec 13. Review. — View Citation

Viggiano E, Marabotti A, Burlina AP, Cazzorla C, D'Apice MR, Giordano L, Fasan I, Novelli G, Facchiano A, Burlina AB. Clinical and molecular spectra in galactosemic patients from neonatal screening in northeastern Italy: structural and functional characterization of new variations in the galactose-1-phosphate uridyltransferase (GALT) gene. Gene. 2015 Apr 1;559(2):112-8. doi: 10.1016/j.gene.2015.01.013. Epub 2015 Jan 13. — View Citation

Yang D, Sun YY, Bhaumik SK, Li Y, Baumann JM, Lin X, Zhang Y, Lin SH, Dunn RS, Liu CY, Shie FS, Lee YH, Wills-Karp M, Chougnet CA, Kallapur SG, Lewkowich IP, Lindquist DM, Murali-Krishna K, Kuan CY. Blocking lymphocyte trafficking with FTY720 prevents inflammation-sensitized hypoxic-ischemic brain injury in newborns. J Neurosci. 2014 Dec 3;34(49):16467-81. doi: 10.1523/JNEUROSCI.2582-14.2014. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The total cost for hospitalization	Determination of utilization of healthcare resources in hospital charges in both arms.	At corrected age of 18 months	No
Other	Average days of hospitalization	From hospital to discharge.	At corrected age of 18 months	No
Other	Parents' understanding of study results	Assessed in parent surveys via questions assessing: subjective understanding, importance of understanding.	At corrected age of 3 months	No
Other	Parents' recall of study results	Assessed in parent surveys via questions assessing: results recall	At corrected age of 3 months	No
Primary	Mortality	The relative frequency of deaths in each group.	At corrected age of 18 months	No
Primary	Disability Rate	Disability, defined as a physical or mental handicap, especially one that prevents a person from living a full,normal life or from holding a gainful job.	At corrected age of 18 months	No
Primary	Number of patients with Gene Mutation	To detect the mutation and characterize the genetic architecture and risk variants of neonatal malformation using different genomic methods.	In 30 days after receipt of the sample	No
Secondary	Neurodevelopment(Bayley Scores)	To evaluate neurodevelopmental function by Bayley Scores of Infant Development Mental Development Index(MDI), gain Incidence of MDI<70(Severe) or DI<85(Moderate)	At corrected age of 18 months	No
Secondary	Respiratory Support	To observe whether the clinical monitoring will be changed with respiratory support after results disclosure	In 14 days after results disclosure	No
Secondary	Care Level	To observe whether the care level will be changed after results disclosure	In 14 days after results disclosure	No